An article in the June 16, 2004, issue of BioWorld Today should have said that in investigator-initiated studies, InterMune saw response rates in the 25 percent to 40 percent range for daily use of Infergen in combination with ribavirin in hepatitis C patients who had failed to respond to a previous course of therapy of pegylated interferon alga-2 plus ribavirin. Also, InterMune s Phase III trial is designed to evaluate once-daily use of Infergen in combination with ribavirin for those same type of patients for 48 weeks with six months of follow up.